Physician profile
Marc Boisvert
NPI 1780658542
$18,287.00
in general payments reported to CMS, 2019-2025
12 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $230 · 2021: $12K · 2022: $4,549 · 2023: $1,031 · 2024: $222 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $930 · Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $930.00 |
| Food and Beverage | $528.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leica Microsystems INC. | $11,939.45 | 2019-2024 | Hydromark Breast Biopsy Site Marker |
| Endomagnetics LTD | $4,648.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $960.04 | 2023-2024 | |
| Ge Healthcare | $200.69 | 2020 | |
| Stryker Corporation | $134.35 | 2021 | |
| Novartis Pharmaceuticals Corporation | $119.60 | 2023-2025 | |
| Stemline Therapeutics INC. | $87.22 | 2023-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $67.16 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $51.07 | 2023-2025 | Itovebi, Phesgo |
| Myriad Genetic Laboratories, INC. | $39.61 | 2024-2025 | Myrisk |
| Celgene Corporation | $23.33 | 2025 | Opdivo |
| Puma Biotechnology, INC. | $16.35 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Boisvert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.